Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.36 USD
Change Today -0.14 / -1.87%
Volume 233.3K
XNPT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

xenoport inc (XNPT) Snapshot

Open
$7.47
Previous Close
$7.50
Day High
$7.57
Day Low
$7.33
52 Week High
01/14/15 - $9.60
52 Week Low
05/9/14 - $3.15
Market Cap
461.9M
Average Volume 10 Days
270.9K
EPS TTM
$-0.82
Shares Outstanding
62.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XENOPORT INC (XNPT)

xenoport inc (XNPT) Related Businessweek News

No Related Businessweek News Found

xenoport inc (XNPT) Details

XenoPort, Inc., a biopharmaceutical company, focuses on developing and commercializing a portfolio of product candidates for the treatment of neurological and other disorders. It offers HORIZANT (gabapentin enacarbil) extended-release tablets for the treatment of moderate-to-severe primary restless legs syndrome in adults and for the management of postherpetic neuralgia in adults. The company is also developing XP23829, a fumaric acid ester compound and a patented prodrug of monomethyl fumarate, which is in Phase I clinical trials for the treatment of psoriasis and relapsing forms of multiple sclerosis. In addition, it is developing arbaclofen placarbil product that is in Phase III clinical trials used for the treatment of spasticity in multiple sclerosis; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson’s disease has completed Phase II clinical trials. The company has a license agreement with Indivior PLC to develop and commercialize pharmaceutical products containing arbaclofen placarbil; license agreement with Astellas Pharma Inc. to develop and commercialize Gabapentin Enacarbil under the Regnite name in Japan; and collaboration agreement with Glaxo Group Limited to develop and commercialize gabapentin enacarbil. XenoPort, Inc. was founded in 1999 and is based in Santa Clara, California.

152 Employees
Last Reported Date: 02/27/15
Founded in 1999

xenoport inc (XNPT) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $500.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $380.3K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $439.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $364.2K
Senior Vice President of Regulatory Affairs &...
Total Annual Compensation: $346.1K
Compensation as of Fiscal Year 2014.

xenoport inc (XNPT) Key Developments

XenoPort, Inc. Proposes Amendments to Amended and Restated Certificate of Incorporation

The 2015 annual meeting of stockholders of XenoPort, Inc. will be held on May 19, 2015. At the meeting the shareholders will approve an amendment to the company's amended and restated certificate of incorporation to eliminate the supermajority voting requirement for amendments to the company's amended and restated bylaws and the shareholders will approve an amendment to the company's amended and restated certificate of incorporation to increase the total number of shares of common stock authorized for issuance from 100 million shares to 200 million shares.

Xenoport, Inc. Announces Resignation of Gianna M. Bosko as Senior Vice President, Chief Legal Officer and Secretary, Effective as of February 28, 2015

On February 13, 2015, Xenoport, Inc. announced Gianna M. Bosko notified the Company of her decision to resign from her position as senior vice president, chief legal officer and secretary of the Company, effective as of February 28, 2015. Pursuant to a consulting agreement, made effective March 1, 2015, Ms. Bosko will be available through March 1, 2016 to provide additional consulting services to the Company in the field of general legal, corporate governance and business matters, at a rate of $500.00 per hour.

Xenoport, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Sales Guidance for the Year 2015

Xenoport, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, total revenues were $7,091,000 against $2,879,000 a year ago. The increase in revenues in the fourth quarter ended December 31, 2014 was principally due to HORIZANT net product sales. Loss from operation was $17,595,000 against $19,059,000 a year ago. Net loss was $17,657,000 or $0.28 per basic and diluted share against $19,138,000 or $0.40 per basic and diluted share a year ago. For the year, total revenues were $46,868,000 against $7,951,000 a year ago. Loss from operation was $49,099,000 against $85,628,000 a year ago. The increase in revenues for the year ended December 31, 2014 was principally due both to the recognition of $25.0 million in collaboration revenue related to an arbaclofen placarbil (AP) licensing agreement with Indivior, as well as to increased HORIZANT net product sales. Net loss was $49,333,000 or $0.81 per basic and diluted share against $85,883,000 or $1.81 per basic and diluted share a year ago. The company announced that it expects HORIZANT net product sales for 2015 to be in the range of $39.0 million to $43.0 million and the net use of cash for 2015 to be in the range of $75.0 million to $85.0 million (net use of cash is the difference between the anticipated balances of cash and cash equivalents plus short-term investments at December 31, 2015, excluding the net proceeds from the sale of the convertible notes completed in February 2015, and the actual balances at December 31, 2014).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XNPT:US $7.36 USD -0.14

XNPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioDelivery Sciences International Inc $9.26 USD +0.05
Depomed Inc $27.65 USD +0.355
Flamel Technologies SA $15.88 USD +0.02
PlasmaTech Biopharmaceuticals Inc $3.78 USD +0.15
Skyepharma PLC 320.50 GBp +2.75
View Industry Companies
 

Industry Analysis

XNPT

Industry Average

Valuation XNPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.0x
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XENOPORT INC, please visit www.xenoport.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.